Correlation Between Inozyme Pharma and Cytokinetics
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Cytokinetics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Cytokinetics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Cytokinetics, you can compare the effects of market volatilities on Inozyme Pharma and Cytokinetics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Cytokinetics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Cytokinetics.
Diversification Opportunities for Inozyme Pharma and Cytokinetics
0.45 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Inozyme and Cytokinetics is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Cytokinetics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytokinetics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Cytokinetics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytokinetics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Cytokinetics go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Cytokinetics
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Cytokinetics. In addition to that, Inozyme Pharma is 1.93 times more volatile than Cytokinetics. It trades about -0.19 of its total potential returns per unit of risk. Cytokinetics is currently generating about -0.03 per unit of volatility. If you would invest 5,063 in Cytokinetics on December 2, 2024 and sell it today you would lose (463.00) from holding Cytokinetics or give up 9.14% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Inozyme Pharma vs. Cytokinetics
Performance |
Timeline |
Inozyme Pharma |
Cytokinetics |
Inozyme Pharma and Cytokinetics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inozyme Pharma and Cytokinetics
The main advantage of trading using opposite Inozyme Pharma and Cytokinetics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Cytokinetics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will offset losses from the drop in Cytokinetics' long position.Inozyme Pharma vs. Beam Therapeutics | Inozyme Pharma vs. Editas Medicine | Inozyme Pharma vs. Caribou Biosciences | Inozyme Pharma vs. Verve Therapeutics |
Cytokinetics vs. Edgewise Therapeutics | Cytokinetics vs. Dyne Therapeutics | Cytokinetics vs. Stoke Therapeutics | Cytokinetics vs. Pliant Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Complementary Tools
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |